CDKN2A and breast cancer: p16, mainly inhibits CDK4 activity, the loss of p16 expression reduced the response of breast cancer cells to PTX by conferring cancer stem cell properties and the tumorsphere formation was not significantly enhanced [49], those results indicated that CKIs affect PTX efficacy mainly through the cell cycle regulation.